1.Wang L, Zhang H, Ruan Y, et al.: Tuberculosis prevalence in China, 1990–2010; a longitudinal analysis of national survey data. Lancet 383: 2057–2064, 2014.
2.Schito M, Migliori GB, Fletcher HA, et al.: Perspectives on Advances in Tuberculosis Diagnostics, Drugs, and Vaccines. Clin Infect Dis 61Suppl 3: S102–118, 2015.
3.Sarich TC, Zhou T, Adams SP, Bain AI, Wall RA and Wright JM: A model of isoniazid-induced hepatotoxicity in rabbits. J Pharmacol Toxicol Methods 34: 109–116, 1995.
4.Timmins GS, Master S, Rusnak F and Deretic V: Nitric oxide generated from isoniazid activation by KatG: source of nitric oxide and activity against Mycobacterium tuberculosis. Antimicrob Agents Chemother 48: 3006–3009, 2004.
5.Suarez J, Ranguelova K, Jarzecki AA, et al.: An Oxyferrous Heme/Protein-based Radical Intermediate Is Catalytically Competent in the Catalase Reaction of Mycobacterium tuberculosis Catalase-Peroxidase (KatG). Journal of Biological Chemistry 284: 7017–7029, 2009.
6.Nahid P, Dorman SE, Alipanah N, et al.: Executive Summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clinical Infectious Diseases 63: e147, 2016.
7.JR M, HJ Z, KG I, et al.: Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis. Annals of Internal Medicine 84: 181, 1976.
8.Ahmad J, Bach N, Bansal M, et al.: Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study. Gastroenterology 148: 1340–1352.e1347, 2015.
9.Yashika G, Rajeshwari G, Sourabh J and Arun K: A rare case of isoniazid-induced erythroderma. Indian Journal of Pharmacology 47: 682–684, 2015.
10.Li F, Wang P, Liu K, et al.: A high dose of isoniazid disturbs endobiotic homeostasis in mouse liver. Drug Metabolism & Disposition 44: 1742, 2016.
11.Mathad JS and Gupta A: Tuberculosis in pregnant and postpartum women: epidemiology, management, and research gaps. Clin Infect Dis 55: 1532–1549, 2012.
12.Zou Y, Zhang Y, Han LW, et al.: Impact of isoniazid on developmental toxicity and behavior of zebrafish larvae. Shandong Science2016.
13.Strecker R, Weigt S and Braunbeck T: Cartilage and bone malformations in the head of zebrafish ( Danio rerio) embryos following exposure to disulfiram and acetic acid hydrazide. Toxicology & Applied Pharmacology 268: 221–231, 2013.
14.Bjornard K, Riehle-Colarusso T, Gilboa SM and Correa A: Patterns of congenital heart defects, Metropolitan Atlanta, 1978 to 2005. Birth Defects Research Part A Clinical & Molecular Teratology 97: 87–94, 2013.
15.Moons P, Sluysmans TW, D, Massin M, Suys B, Benatar A and Gewillig M: Congenital heart disease in 111 225 births in Belgium: birth prevalence, treatment and survival in the 21st century. Acta Pã¦diatrica 98: 472–477, 2009.
16.Shah GS, Singh MK, Pandey TR, Kalakheti BK and Bhandari GP: Incidence of congenital heart disease in tertiary care hospital. Kathmandu University Medical Journal 6: 33–36, 2008.
17.Sanchez‐Castro M, Pichon O, Briand A, et al.: Disruption of the SEMA3D Gene in a Patient with Congenital Heart Defects. Human Mutation 36: 30–33, 2015.
18.Källén BA and Otterblad OP: Maternal drug use in early pregnancy and infant cardiovascular defect. Reproductive Toxicology 17: 255–261, 2003.
19.Ibrahim AE and Abdel-Daim MM: Modulating Effects of Spirulina platensis against Tilmicosin-Induced Cardiotoxicity in Mice. Cell journal 17: 137–144, 2015.
20.Abushouk AI, Ismail A, Salem AMA, Afifi AM and Abdel-Daim MM: Cardioprotective mechanisms of phytochemicals against doxorubicin-induced cardiotoxicity. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 90: 935–946, 2017.
21.Abdellatief SA, Galal AA, Farouk SM and Abdel-Daim MM: Ameliorative effect of parsley oil on cisplatin-induced hepato-cardiotoxicity: A biochemical, histopathological, and immunohistochemical study. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 86: 482–491, 2017.
22.Schwerte T and Pelster B: Digital motion analysis as a tool for analysing the shape and performance of the circulatory system in transparent animals. Journal of Experimental Biology 203: 1659–1669, 2000.
23.Development: Test No.203: Fish, Acute Toxicity Test. Oecd Guidelines for the Testing of Chemicals volume 1: 1–10(10), 1992.
24.Shah I, Jadhao N, Mali N, Deshpande S, Gogtay N and Thatte U: Pharmacokinetics of isoniazid in Indian children with tuberculosis on daily treatment. The international journal of tuberculosis and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease 23: 52–57, 2019.
25.Bakkers J: Zebrafish as a model to study cardiac development and human cardiac disease. Cardiovasc Res 91: 279–288, 2011.
26.Buckingham M, Meilhac S and Zaffran S: Building the mammalian heart from two sources of myocardial cells. Nat Rev Genet 6: 826–835, 2005.
27.Vincent SD and Buckingham ME: How to make a heart: the origin and regulation of cardiac progenitor cells. Current topics in developmental biology 90: 1–41, 2010.
28.Bruneau BG: Signaling and transcriptional networks in heart development and regeneration. Cold Spring Harb Perspect Biol 5: a008292, 2013.
29.Olson EN: Gene regulatory networks in the evolution and development of the heart. Science 313: 1922–1927, 2006.
30.Waardenberg AJ, Ramialison M, Bouveret R and Harvey RP: Genetic networks governing heart development. Cold Spring Harb Perspect Med 4: a013839, 2014.
31.Bruneau BG: The developmental genetics of congenital heart disease. Nature 451: 943–948, 2008.
32.Olguin-Albuerne M and Moran J: ROS produced by NOX2 control in vitro development of cerebellar granule neurons development. ASN Neuro 72015.
33.Daugaard M, Nitsch R, Razaghi B, et al.: Hace1 controls ROS generation of vertebrate Rac1-dependent NADPH oxidase complexes. Nat Commun 4: 2180, 2013.
34.Razaghi B, Steele SL, Prykhozhij SV, et al.: hace1 Influences zebrafish cardiac development via ROS-dependent mechanisms. Dev Dyn 247: 289–303, 2018.
35.Zennaro C, Mariotti M, Carraro M, et al.: Podocyte developmental defects caused by adriamycin in zebrafish embryos and larvae: a novel model of glomerular damage. PLoS One 9: e98131, 2014.
36.Jin Y, Liu Z, Peng T and Fu Z: The toxicity of chlorpyrifos on the early life stage of zebrafish: a survey on the endpoints at development, locomotor behavior, oxidative stress and immunotoxicity. Fish Shellfish Immunol 43: 405–414, 2015.